To include your compound in the COVID-19 Resource Center, submit it here.

ETC-588 large unilamellar vesicles: ESPR began a dose-ranging U.S. Phase II trial of ETC-588 in 32 patients with vascular disease. Patients will receive an intr

Esperion Therapeutics Inc. (ESPR), Ann Arbor, Mich.
Product: ETC-588 large unilamellar

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE